NRXN1 and breast cancer: For the ROC curve for no metastases and distant organ metastases of BC, the sensitivity and specificity of the NRXN-1 were 70% and 66%, at the best possible cutoff value of 13.36 -fold increase in NRXN-1 expression, respectively (AUC = 0.79, p < 0.0001) (Table 6) and for ROC curve for CNTN-1 w.r.t early stage versus advanced stage of breast cancer at the best possible cutoff value of a 5.7-fold increase in CNTN-1 expression, the sensitivity and specificity were 75% and 74%, respectively (AUC = 0.86, p < 0.0001) (Figure 5).